The Financial Comet
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

The Financial Comet

Politics

FDA phasing out some animal testing in ‘win-win’ for ethics and public health: commissioner

by admin April 11, 2025
April 11, 2025
FDA phasing out some animal testing in ‘win-win’ for ethics and public health: commissioner

— The Food and Drug Administration is phasing out an animal testing requirement for antibody therapies and other drugs in favor of testing on materials that mimic human organs, the FDA announced on Thursday. 

‘For too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,’ FDA Commissioner Martin A. Makary, said in comment provided to Fox News Digital. 

 ‘By leveraging AI-based computational modeling, human organ model-based lab testing, and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&D costs and drug prices. It is a win-win for public health and ethics.’ 

The phase-out focuses on ending animal testing in regard to researching monoclonal antibody therapies, which are lab-made proteins meant to stimulate the immune system to fight diseases such as cancer, as well as other drugs, according to the press release. 

Instead, the FDA will encourage testing on ‘organoids,’ which are artificially grown masses of cells, according to the FDA’s press release obtained by Fox Digital. 

‘The FDA will promote the use of lab-grown human ‘organoids’ and organ-on-a-chip systems that mimic human organs – such as liver, heart, and immune organs – to test drug safety. These experiments can reveal toxic effects that could easily go undetected in animals, providing a more direct window into human responses,’ the press release says. 

The FDA will also encourage the use of AI while testing drugs, including building computer modeling that can predict a drug’s behavior, Fox Digital learned. 

The phase-out will include updating its guidelines to recognize research conducted on organoids and through AI.

‘Companies that submit strong safety data from non-animal tests may receive streamlined review, as the need for certain animal studies is eliminated, which would incentivize investment in modernized testing platforms,’ the FDA explained in its press release. 

The FDA is slated to also work with fellow federal agencies, such as the National Institutes of Health, the National Toxicology Program and the Department of Veterans Affairs, to ‘accelerate the validation’ of the new testing standards and will hold a public workshop later this year to further discuss the matter. 

‘For patients, it means a more efficient pipeline for novel treatments. It also means an added margin of safety, since human-based test systems may better predict real-world outcomes. For animal welfare, it represents a major step toward ending the use of laboratory animals in drug testing. Thousands of animals, including dogs and primates, could eventually be spared each year as these new methods take root,’ Makary said. 

This post appeared first on FOX NEWS

previous post
China ramps up military ‘rehearsals’ around Taiwan, outstrips US in air, maritime, space
next post
In a first, Taiwan charges Chinese ship captain with damaging undersea cables

Related Posts

Abbey Gate terrorist, human smuggling ring leaders, cartel...

March 11, 2025

Trump’s spending bill heads to Senate where Republicans...

June 10, 2025

Trump nominates Susan Monarez to become the next...

March 25, 2025

Trump will determine if Putin is ‘serious about...

February 17, 2025

Next US national security advisor? Here’s who Trump...

May 2, 2025

Skyrocketing antisemitism in Canada sparks concern for country’s...

April 21, 2025

Trump touts ‘rebuilding and modernization’ of US air...

May 9, 2025

Judge extends order blocking Musk’s DOGE team from...

February 15, 2025

Trump so far has freed 11 hostages in...

February 15, 2025

Trump 100% disagrees with federal judge’s ‘crazy’ ruling...

February 10, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 2

      DeepSeek hit with large-scale cyberattack, says it’s limiting registrations

      January 28, 2025
    • 3

      Bank of America CEO says financial industry will jump into crypto payments if regulators allow it

      January 23, 2025
    • 4

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • 5

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 27, 2025
    • 6

      UnitedHealthcare taps company veteran Tim Noel as new CEO following Brian Thompson killing

      January 27, 2025
    • 7

      Lara Trump to host weekend show on Fox News

      February 7, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: thefinancialcomet.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 thefinancialcomet.com | All Rights Reserved